Novartis Ag (NVSEF) Long-Term Investments (2009 - 2026)

Novartis Ag has disclosed Long-Term Investments across 14 years of filings, most recently posting $100.0 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $100.0 million, down 12.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.0 million (down 12.28% YoY), and the FY2025 annual result was $98.0 million, down 17.65% from the prior year.
• Long-Term Investments came in at $100.0 million for Q1 2026 at Novartis Ag, up from $98.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $205.0 million in Q4 2023 to a low of $85.0 million in Q3 2025.
• The 5-year median for Long-Term Investments is $119.0 million (2024), against an average of $130.9 million.
• Across the five-year window, Long-Term Investments tumbled 98.17% in 2022 and jumped 43.36% in 2023, its largest moves.
• Novartis Ag's Long-Term Investments stood at $143.0 million in 2022, then surged by 43.36% to $205.0 million in 2023, then sank by 41.95% to $119.0 million in 2024, then declined by 17.65% to $98.0 million in 2025, then gained by 2.04% to $100.0 million in 2026.
• The last three Long-Term Investments figures came in at $100.0 million (Q1 2026), $98.0 million (Q4 2025), and $85.0 million (Q3 2025), per Business Quant data.